MX2022011488A - Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos. - Google Patents

Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.

Info

Publication number
MX2022011488A
MX2022011488A MX2022011488A MX2022011488A MX2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A
Authority
MX
Mexico
Prior art keywords
analogs
viral infections
treating viral
monosaccharides
hexose
Prior art date
Application number
MX2022011488A
Other languages
English (en)
Spanish (es)
Inventor
Donald Picker
Walter Klemp
Rafal Zielinski
Waldemar Priebe
Izabela Fokt
Stanislaw Skora
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2022011488A publication Critical patent/MX2022011488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022011488A 2020-03-16 2021-03-16 Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos. MX2022011488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (1)

Publication Number Publication Date
MX2022011488A true MX2022011488A (es) 2023-03-01

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011488A MX2022011488A (es) 2020-03-16 2021-03-16 Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.

Country Status (11)

Country Link
US (1) US20230130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121060A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023518249A (cg-RX-API-DMAC10.html)
KR (1) KR20220166800A (cg-RX-API-DMAC10.html)
CN (1) CN115515601B (cg-RX-API-DMAC10.html)
AU (1) AU2021239927A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018536A2 (cg-RX-API-DMAC10.html)
CA (1) CA3170872A1 (cg-RX-API-DMAC10.html)
IL (1) IL296389A (cg-RX-API-DMAC10.html)
MX (1) MX2022011488A (cg-RX-API-DMAC10.html)
WO (1) WO2021188586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
ATE544865T1 (de) * 2002-07-12 2012-02-15 Us Gov Health & Human Serv Assays für den zusammenbau von ebola-virus- nukleocapsiden
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US8173636B2 (en) * 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Also Published As

Publication number Publication date
JP2023518249A (ja) 2023-04-28
CN115515601A (zh) 2022-12-23
CN115515601B (zh) 2026-06-16
IL296389A (en) 2022-11-01
AU2021239927A1 (en) 2022-10-06
EP4121060A1 (en) 2023-01-25
KR20220166800A (ko) 2022-12-19
BR112022018536A2 (pt) 2022-11-29
US20230130134A1 (en) 2023-04-27
WO2021188586A1 (en) 2021-09-23
CA3170872A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
Mehrzadi et al. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin
Morandini et al. The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases
PH12018550205A1 (en) Synergistic antifungal compositions and methods thereof
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
BR112022018536A2 (pt) Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos
CL2020001145A1 (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
BR112016022976A8 (pt) métodos para o tratamento de hcv
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112018071997A2 (pt) nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
BR112015020918A2 (pt) métodos para tratar o hcv
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112018000383A2 (pt) métodos para tratar hcv
MX2023009499A (es) Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.
BR112014027646A2 (pt) método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
WO2020055547A3 (en) Methods and compositions for honey bee health
MX2022000232A (es) Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir.
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
UY38439A (es) Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
CO2022002934A2 (es) Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta